Search Within

Heiko Schoder

  1. "2021"
Formats
  1. Journal Article (18)
  2. Meeting Abstract (18)
  3. Review (8)
  4. Editorial (3)
  5. Guidelines (2)
  6. Miscellaneous (1)
  7. Research Letter (1)
Groups
  1. Molecular Imaging and Therapy Service (51)
  2. Radiology, Department of (51)
  3. Sloan Kettering Institute Postdocs (24)
  4. Department of Medicine (21)
  5. Survivorship Research (16)
  6. Center for Pancreatic Cancer Research (13)

More Groups

People
  1. Alison Moskowitz (11)
  2. Ariela Noy (9)
  3. David Straus (8)
  4. Steven Horwitz (8)
  5. Andrew Zelenetz (7)
  6. Anita Kumar (7)

More People

Years
  1. 2021 (51)
Publications
  1. Journal of Clinical Oncology (8)
  2. Blood (7)
  3. European Journal of Nuclear Medicine and Molecular Imaging (7)
  4. Hematological Oncology (4)
  5. Journal of Nuclear Medicine (4)
  6. Quarterly Journal of Nuclear Medicine and Molecular Imaging (2)

More Publications

Publishers
  1. Springer (9)
  2. American Society of Clinical Oncology (8)
  3. American Society of Hematology (7)
  4. Elsevier Inc. (4)
  5. Society of Nuclear Medicine (4)
  6. Wiley Blackwell (4)

More Publishers

Results (51)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Positron emission tomography and magnetic resonance imaging in primary central nervous system lymphoma—A narrative review
    Review

    Krebs, S.; Barasch, J. G.; Young, R. J.; Grommes, C.; Schöder, H.
    Annals of Lymphoma (2021)

    Fulltext@MSK | Save
  • Quantitative change in metabolic tumor volume may assist in distinguishing between pseudoprogressors and responders in patients with relapsed/refractory classical Hodgkin lymphoma treated with PD-1 blockade
    Meeting Abstract

    Wills, B.; Michaud, L.; Schöder, H.; Ganesan, N.; Moskowitz, C. H.; Straus, D. J.; Falchi, L.; Matasar, M. J.; Zelenetz, A. D.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Metabolic tumor volume and total lesion glycolysis can predict response to very low dose radiotherapy (4 Gy) in indolent B-cell lymphomas
    Meeting Abstract

    Wijetunga, N. A.; Imber, B. S.; Lee, J.; Hajj, C.; Mayerhoefer, M. E.; Schoder, H.; Yahalom, J.
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Effect of brentuximab vedotin addition to chemotherapy and prognostic factors in patients with relapsed/refractory hodgkin lymphoma: A large multi-trial analysis based on individual patient data
    Meeting Abstract

    Driessen, J.; de Wit, F.; Herrera, A. F.; Zinzani, P. L. L.; LaCasce, A. S.; Moskowitz, C. H.; Garcia-Sanz, R.; Cole, P. D.; Fuchs, M.; Mueller, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Trial-in-progress: Randomized phase II trial in early relapsing or refractory follicular lymphoma (NCT# 03269669): SWOG S1608
    Meeting Abstract

    Barr, P. M.; Li, H.; Link, B. K.; Flowers, C. R.; Burack, R.; Schöder, H.; Leblanc, M. L.; Weigert, O.; Herrera, A. F.; Weinstock, D. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Precision radiotherapy: Reduction in radiation for oropharyngeal cancer in the 30 ROC trial
    Journal Article

    Riaz, N.; Sherman, E.; Pei, X.; Schöder, H.; Grkovski, M.; Paudyal, R.; Katabi, N.; Selenica, P.; Yamaguchi, T. N.; Ma, D.; more...
    JNCI: Journal of the National Cancer Institute (2021)

    Fulltext@MSK | Save
  • A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas
    Journal Article

    Moskowitz, A. J.; Ghione, P.; Jacobsen, E.; Ruan, J.; Schatz, J. H.; Noor, S.; Myskowski, P.; Vardhana, S.; Ganesan, N.; Hancock, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Blood based genomic assessment of the clinical efficacy and toxicity of peptide receptor radionuclide therapy (PRRT)
    Meeting Abstract

    Bodei, L.; Raj, N.; Do, R. K. G.; Krebs, S.; Reidy, D.; Kidd, M.; Drozdov, I.; Modlin, I.; Schoder, H.
    Journal of Nuclear Medicine (2021)

    Fulltext@MSK | Save